PCMU
BMRN icon

Paragon Capital Management (Utah)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Paragon Capital Management (Utah)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Sell
24,200
-504
-2% -$27.6K 1.03% 26
2026
Q1 		$1.4M Buy
24,704
+4,664
+23% +$272K 1.18% 21
2025
Q4 		$1.19M Buy
+20,040
New +$1.09M 0.92% 40

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM

Paragon Capital Management (Utah)'s BMRN Position: Q2 2026 in Review

Paragon Capital Management (Utah) reduced its BioMarin Pharmaceuticals (BMRN) stake by 2% in Q2 2026, selling an estimated $27.6K and leaving 24,200 shares worth $1.38M. The position accounts for 1.03% of the portfolio, ranked #26.

Paragon Capital Management (Utah) first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.4M in Q1 2026. 228 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Paragon Capital Management (Utah) held 24,200 shares of BioMarin Pharmaceuticals worth $1.38M as of Q2 2026.
  • Paragon Capital Management (Utah) sold 504 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $27.6K.
  • BioMarin Pharmaceuticals made up 1.03% of Paragon Capital Management (Utah)'s portfolio in Q2 2026, its #26 holding.
  • Paragon Capital Management (Utah) first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Paragon Capital Management (Utah)'s BioMarin Pharmaceuticals position peaked at $1.4M in Q1 2026.
  • 228 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Paragon Capital Management (Utah)'s 13F filing for Q2 2026, filed 22 Jul 2026.